Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction?

× No keyword cloud information.

17 in total

1. ⁶⁸Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with ¹¹¹In-octreotide SPECT/CT and conventional imaging.

Authors: Lilian Yuri Itaya Yamaga; Marcelo L Cunha; Guilherme C Campos Neto; Marcio R T Garcia; Ji H Yang; Cleber P Camacho; Jairo Wagner; Marcelo B G Funari
Journal: Eur J Nucl Med Mol Imaging Date: 2017-04-20 Impact factor: 9.236

2. The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the "evidence-based" refusal to endorse them by EANM due to the "not evidence-based" marginalization of the role of Nuclear Medicine.

Authors: Giorgio Treglia; Cumali Aktolun; Arturo Chiti; Savvas Frangos; Luca Giovanella; Martha Hoffmann; Ioannis Iakovou; Jasna Mihailovic; Bernd J Krause; Werner Langsteger; Frederik A Verburg; Markus Luster
Journal: Eur J Nucl Med Mol Imaging Date: 2016-04-27 Impact factor: 9.236

3. 2012 European thyroid association guidelines for metastatic medullary thyroid cancer.

Authors: M Schlumberger; L Bastholt; H Dralle; B Jarzab; F Pacini; J W A Smit
Journal: Eur Thyroid J Date: 2012-03-28

Review 4. What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma?

Authors: K Slavikova; F Montravers; G Treglia; J Kunikowska; L Kaliska; M Vereb; J N Talbot; S Balogova
Journal: Curr Radiopharm Date: 2013-06-06

5. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid.

Authors: M Papotti; U Kumar; M Volante; C Pecchioni; Y C Patel
Journal: Clin Endocrinol (Oxf) Date: 2001-05 Impact factor: 3.478

Review 6. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis.

Authors: Giorgio Treglia; Maria Felicia Villani; Alessandro Giordano; Vittoria Rufini
Journal: Endocrine Date: 2012-04-17 Impact factor: 3.633

7. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt.

Authors: M C Zatelli; F Tagliati; J E Taylor; R Rossi; M D Culler; E C degli Uberti
Journal: J Clin Endocrinol Metab Date: 2001-05 Impact factor: 5.958

Review 8. Peptide Receptor Radionuclide Therapy (PRRT) of Medullary and Nonmedullary Thyroid Cancer Using Radiolabeled Somatostatin Analogues.

Authors: Ali Salavati; Ameya Puranik; Harshad R Kulkarni; Hendra Budiawan; Richard P Baum
Journal: Semin Nucl Med Date: 2016-05 Impact factor: 4.446

9. Early, Prophylactic Thyroidectomy in Hereditary Medullary Thyroid Carcinoma: A 26-year Monoinstitutional Experience.

Authors: Maria R Pelizzo; Francesca Torresan; Isabella M Boschin; Davide Nacamulli; Gianmaria Pennelli; Susi Barollo; Domenico Rubello; Caterina Mian
Journal: Am J Clin Oncol Date: 2015-10 Impact factor: 2.339

10. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging.

Authors: M C Marzola; M R Pelizzo; M Ferdeghini; A Toniato; A Massaro; V Ambrosini; S Fanti; M D Gross; A Al-Nahhas; D Rubello
Journal: Eur J Surg Oncol Date: 2010-01-25 Impact factor: 4.424

1 in total

1. Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma.

Authors: Constantin Lapa; Rudolf A Werner; Sebastian E Serfling; Yingjun Zhi; Felix Megerle; Martin Fassnacht; Andreas K Buck
Journal: Endocrine Date: 2022-06-25 Impact factor: 3.925

1 in total